Ben,

this is just a "quicky".  I don't have time to go in depth on these folks.

Just because they come up clean, doesn't mean much.

I'll try to get to the pediatric committee later,
but I'm jammed.

Vince



http://www.fda.gov/cder/audiences/acspage/psychopharmroster1.htm
Psychopharmacologic Drugs Advisory Committee Roster
Chair: Wayne K. Goodman, M.D.

Wayne K. Goodman, M.D., Chair, Department of Psychiatry, McKnight Brain Institute, University of Florida College of Medicine, Gainesville, FL.  Member of the FDA's Psychopharmacologic Drugs Advisory Committee (Term: 01/12/04 - 06/30/06). (http://www.fda.gov/cder/audiences/acspage/psychopharmroster1.htm; accessed 01/28/04) Recent research projects include: use of escitalopram in compulsive gamblers (funded by Forest Laboratories); tests of CP 448,187 for obsessive compulsive disorder (funded by Pfizer); combination venlafaxine and sertraline for treatment of PTSD (funded by Wyeth-Ayerst); and paroxetine for generalized anxiety disorder (funded by GlaxoSmithKline). (http://www.fda.gov/cder/audiences/acspage/CVs/Goodman.pdf; accessed 12/5/2005) Research on the safety of sertraline (Zoloft) in long-term obsessive-compulsive disease treatment, presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting of National Institutes of Mental Health (1999), was funded By Pfizer. (http://www.nimh.nih.gov/events/ncdeu99abstracts.pdf; accessed 1/28/04)

Expertise:  Psychiatry
Term:  08/19/04 - 06/30/06
Chair, Department of Psychiatry
University of Florida College of Medicine
McKnight Brain Institute
Suite L4-100
100 Newell Drive
Gainesville, Florida 32611

Executive Secretary
Cicely Reese, Pharm.D. None found)
Advisors and Consultants Staff
Center for Drug Evaluation and Research
Food and Drug Administration, HFD-021
5600 Fishers Lane
Rockville, Maryland 20857
E-mail: Reeseci@cder.fda.gov
(301) 827-7001
Fax: (301) 827-6776

Jorge Armenteros, M.D.  none found)
Expertise:  Psychiatry & Behavioral Medicine
Term:  01/23/06 - 06/30/09
2199 Ponce De Leon Boulevard
Suite 304
Coral Gables, Florida 33134

* Jean Bronstein, R.N., M.S.(none found)
Expertise:  Consumer Representative
Term: 01/12/04 - 06/30/07
814 Beaverton Court
Sunnyvale, California 94097

Andrew C. Leon, Ph.D.
Expertise:  Biostatistics
Term:  01/12/04 - 06/30/07
Professor, Department of Psychiatry
Weill Medical College of Cornell University
525 East 68th Street, Box 140
New York, New York 10021
  

Andrew Leon, Ph.D., Professor of Biostatistics in Psychiatry and Professor of Public Health, Weill Medical School, Cornell University, Ithaca, NY. Consultant to Cyberonics, Inc., and Cortex Pharmaceuticals. Completed a manuscript and presentation for Forest Laboratories titled, "Are Two Antidepressant Mechanisms Better than One? Issues in Clinical Trial Design and Analysis." (Preliminary Report of the Task Force on SSRIs and Suicidal Behavior in Youth, American College of Neuropsychopharmacology, 1/21/04, p.16; on file with CSPI)

James J. McGough, M.D.
Expertise:  Child Adolescent Psychiatry
Term:  01/12/04 - 06/30/06
Associate Professor of Clinical Psychiatry
Division of Child and Adolescent Psychiatry
David Geffen School of Medicine at UCLA
300 UCLA Medical Plaza, Suite 1414
Los Angeles, California 90095
  

James J. McGough, M.D., Associate Professor of Clinical Psychiatry, Division of Child and Adolescent Psychiatry, David Geffen School of Medicine, University of California, Los Angeles.  Research on the efficacy of Adderall XR(R) on children with attention-deficit/hyperactivity disorder was funded by the drug’s manufacturer, Shire Pharmaceuticals. (J. Am. Acad. Child Adolesc. Psychiatry 2003;42:6) &nbspGrant/research support from Boston Life Sciences, Eli Lilly, Janssen Pharmaceutica, McNeil Consumer Healthcare, Novartis, and Shire US; consultant to McNeil Consumer Healthcare and Shire US; and speakers bureau for Eli Lilly, McNeil Consumer Healthcare, and Shire US. (http://ccoe.umdnj.edu/rwjms/self%20study/monographs/MC_PediatricADHD.pdf, pg.3; accessed 01/30/04)

**Dilip J. Mehta, M.D., Ph.D.   (none found)
Expertise:  Industry Representative
Term:  02/02/04 - 10/31/07
870 United Nations Plaza
New York, New York 10017

Daniel S. Pine, M.D.    (none found)
Expertise:  Child & Adolescent Psychiatry
Term:  08/19/04 - 06/30/08
Chief of Child & Adolescent Research
National Institutes of Health
National Institutes of Mental Health
Mood and Anxiety Disorders Program
Building 15K, Room 110, MSC-2670
Bethesda, Maryland 20892


Bruce G. Pollock, M.D., Ph.D. (none found)
[PDF]
Expertise:  Geriatric Psychopharmacology
Term:  08/19/04 - 06/30/08
Chief, Academic Division of Geriatrics and Neuropsychiatry
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic
Thomas Detre Hall, E-833
3811 O'Hara Street
Pittsburgh, Pennsylvania 15213

Delbert G. Robinson, M.D. (none found)
[Word] [PDF]
Expertise:  Psychiatry
Term:  08/09/04 - 06/30/08
Associate Professor of Psychiatry
Research Department
The Zucker Hillside Hospital
76th Avenue and 266th Street
Glen Oaks, New York 11004

Philip S. Wang, M.D., M.P.H., Dr. P.H.
Expertise:  Psychiatry and Epidemiology
Term:  01/12/04 - 06/30/07
Associate Physician
Department of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital
1620 Tremont Street, Suite 3030
Boston, Massachusetts 02120
  

Philip S. Wang, M.D., M.P.H., Dr. P.H., Associate Physician, Department of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard University Medical School, Boston, MA.  Served as an expert witness on behalf of SmithKline Beecham (GlaxoSmithKline). (Tobin v. SmithKline Beecham Pharms., U.S. Dist. Ct., D. Wyo.: 48; available at http://www.healyprozac.com/Trials/Tobin/Transcripts/5-29%20Wang-McGrath-Lafferty-RHardy.txt; accessed 01/29/04)

Barbara G. Wells, Pharm.D.   (none found)


Expertise: Psychiatric Pharmacy
Term:  08/19/04 - 06/30/08
Professor and Dean of School of Pharmacy
University of Mississippi
Post Office Box 1848
University, Mississippi 38677

*  Consumer Representative
** Industry Representative